Eledon Reports Updated Data From Ongoing Phase 1b Trial Evaluating Tegoprubart For Prevention Of Rejection In Kidney Transplantation
Portfolio Pulse from Benzinga Newsdesk
Eledon Pharmaceuticals (NASDAQ:ELDN) has reported positive results from its ongoing Phase 1b trial evaluating tegoprubart for the prevention of kidney transplant rejection. The data from 11 participants showed that tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated. The company will continue the study in parallel with its Phase 2 BESTOW study.
November 02, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eledon Pharmaceuticals' positive results from its Phase 1b trial of tegoprubart could potentially boost investor confidence and the company's stock price in the short term.
The positive results from the Phase 1b trial of tegoprubart, a drug developed by Eledon Pharmaceuticals, indicate that the drug is effective and safe for preventing kidney transplant rejection. This could potentially lead to increased investor confidence in the company and a rise in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100